Full Papers
Predictors of post-operative cardiovascular complications for Behçet’s disease with pre-operative immunosuppressive therapy
L. Ye1, F. Chen2, W. Wang3, O. Chen4, H. Qing5, L. Gan6, L. Zhuang7, Y. Cui8, X. Jian9
- Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
- Department of Cardiovascular Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China.
- Chinese Academy of Medical Science, Peking Union Medical College, Fuwai Hospital, Beijing, China.
- Department of Echocardiography, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China.
- Department of Cardiovascular Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China.
- Chinese Academy of Medical Science, Peking Union Medical College, Fuwai Hospital, Beijing, China.
- Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
- Department of Rheumatology and Immunology, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China. 13602835538@139.com
- Department of Cardiovascular Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China. jianxuhuagdgh@126.com
CER18763
2025 Vol.43, N°10
PI 1763, PF 1771
Full Papers
Free to view
(click on article PDF icon to read the article)
PMID: 41133356 [PubMed]
Received: 28/03/2025
Accepted : 05/09/2025
In Press: 23/10/2025
Published: 23/10/2025
Abstract
OBJECTIVES:
Patients with Behçet’s disease (BD) with cardiovascular involvement often have more post-operative complications in correcting the pathology by surgical means. This study aims to explore the benefits of pre-operative immunosuppressive therapy, predict complications using inflammatory biomarkers, and evaluate optimal surgery timing.
METHODS:
This retrospective study analysed predictors of post-operative complications in BD patients who underwent cardiovascular surgery with perioperative immunosuppressive therapy at Guangdong Provincial People’s Hospital from 2012 to 2024.
RESULTS:
In-hospital complications were lower in patients who received pre-operative immunosuppressive therapy (9% vs. 58.8%, p<0.001). Rheumatoid factor (RF, hazard ratio [HR] 1.088; 95% confidence interval [CI], 0.998–1.187; p=0.056), platelet-to-lymphocyte ratio (PLR, HR 1.004; 95% CI, 1.000–1.008; p=0.075), and neutrophil-to-lymphocyte ratio (NLR, HR 1.065; 95% CI, 1.002–1.133; p=0.045) were identified as independent risk factors for post-operative complications, while pre-operative immunosuppressive therapy (HR 0.206; 95% CI, 0.061–0.693; p=0.011) was a protective factor. The area under the curve (AUC) for the receiver operating characteristic curve for four or more positive biomarkers was 0.849.
CONCLUSIONS:
Pre-operative immunosuppressive therapy is vital for BD patients. Monitoring inflammatory biomarkers helps identify the best timing for surgery and reduces complications.
